how long have glp 1 agonists been around GLP-1 Receptor Agonist Market Size History of glucagon-like peptide-1 receptor
Description
Microdosing GLP-1 for Hashimoto's: explore the evidence, potential benefits, safety concerns, and NHS guidance on using GLP-1 receptor agonists for autoimmune thyroid disease and metabolic symptoms.
Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated
Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62
Why Microdosing
Do not reuse
Explore the role of GLP-1 receptor agonists in neuroprotection and their impact on Alzheimer's and Parkinson's diseases.
